CLASS ACTION UPDATE for T, HCSG, NTNX and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
AT&T Inc. (NYSE: T) Class Period: (a) Shares purchased pursuant to the June 2018 acquisition of and merger with Time Warner and/or (b) shares purchased between October 22, 2016 and October 24, 2018 Lead Plaintiff Deadline: May 31, 2019 Join the action: https://www.zlk.com/pslra-1/att-inc-loss-form?wire=3
About the lawsuit: During the class period, AT&T Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) AT&T had substantially increased prices, while at the same time discontinuing promotional discounts for its DirecTV Now service; (ii) as a result, DirecTV Now subscribers were leaving (i.e., not renewing) as soon as their promotional discount periods expired, while at the same time new potential DirecTV Now customers were unwilling to pay the higher prices and therefore not subscribing at all; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the AT&T Inc. class action contact firstname.lastname@example.org.
Healthcare Services Group, Inc. (NASDAQ: HCSG) Class Period: April 11, 2017 - March 4, 2019 Lead Plaintiff Deadline: May 21, 2019 Join the action: https://www.zlk.com/pslra-1/healthcare-services-group-inc-loss-form?wire=3
About the lawsuit: Healthcare Services Group, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (a) Defendant Wahl either knew or was reckless in not knowing that the Company had been accused of strategically rounding quarterly earnings per share, and therefore investors could not rely upon the Company’s track record without conducting a thorough investigation into the allegations; (b) Defendants concealed that the SEC had written to the Company in November 2017 to inquire into the Company’s earnings per share rounding practices; and (c) the Company concealed that the SEC delivered a subpoena to the Company in March 2018 demanding the Company produce documents in connection with how it calculated earnings per share.
To learn more about the Healthcare Services Group, Inc. class action contact email@example.com.
Nutanix, Inc. (NASDAQGS: NTNX) Class Period: Class A shares purchased between March 2, 2018 and February 28, 2019 Lead Plaintiff Deadline: May 28, 2019 Join the action: https://www.zlk.com/pslra-1/nutanix-inc-loss-form?wire=3
The complaint concerns whether the Company and its executives violated federal securities laws by making false and/or misleading statements about its investments in growth and its maintenance of high profit margins. On February 28, 2019, Nutanix announced its second quarter fiscal 2019 results and reported third quarter guidance that was below analysts’ expectations. Management acknowledged that “inadequate marketing spend for pipeline generation and slower than expected sales hiring” were the reasons for the weak guidance. On this news, Nutanix’s share price fell from $50.09 per share on February 28, 2019 to a closing price of $33.70 on March 1, 2019.
To learn more about the Nutanix, Inc. class action contact firstname.lastname@example.org.
Zogenix, Inc. (NASDAQ: ZGNX) Class Period: February 6, 2019 - April 8, 2019 Lead Plaintiff Deadline: June 11, 2019 Join the action: https://www.zlk.com/pslra-1/zogenix-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, Zogenix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the Zogenix, Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 firstname.lastname@example.org Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com